BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15638964)

  • 1. EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection.
    Cuneo KC; Nyati MK; Ray D; Lawrence TS
    Pharmacol Ther; 2015 Oct; 154():67-77. PubMed ID: 26205191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of Cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature.
    Kanakamedala MR; Packianathan S; Vijayakumar S
    Radiat Oncol; 2010 May; 5():38. PubMed ID: 20478052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploiting novel molecular targets in gastrointestinal cancers.
    Ma WW; Hidalgo M
    World J Gastroenterol; 2007 Nov; 13(44):5845-56. PubMed ID: 17990350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer.
    Zhuang H; Zhao X; Zhao L; Chang JY; Wang P
    Drug Des Devel Ther; 2014; 8():667-75. PubMed ID: 24936128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epidermal growth factor receptor conundrum.
    Wilken JA; Baron AT; Maihle NJ
    Cancer; 2011 Jun; 117(11):2358-60. PubMed ID: 24048781
    [No Abstract]   [Full Text] [Related]  

  • 6. The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer.
    Rong Z; Zheng K; Chen J; Jin X
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):154. PubMed ID: 38521878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).
    Wang Q; Zeng A; Zhu M; Song L
    Int J Oncol; 2023 Feb; 62(2):. PubMed ID: 36601768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.
    Falzone L; Salomone S; Libra M
    Front Pharmacol; 2018; 9():1300. PubMed ID: 30483135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers.
    Pan M; Schinke H; Luxenburger E; Kranz G; Shakhtour J; Libl D; Huang Y; Gaber A; Pavšič M; Lenarčič B; Kitz J; Jakob M; Schwenk-Zieger S; Canis M; Hess J; Unger K; Baumeister P; Gires O
    PLoS Biol; 2018 Sep; 16(9):e2006624. PubMed ID: 30261040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
    Kim ES
    Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S80-4. PubMed ID: 15638964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor biology (IMC-C225).
    Kim ES; Khuri FR; Herbst RS
    Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Rossi A; Bria E; Maione P; Palazzolo G; Falanga M; Gridelli C
    Rev Recent Clin Trials; 2008 Sep; 3(3):217-27. PubMed ID: 18782080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.